AJP - Heart and Circulatory Physiology, Vol 267, Issue 5 1955-H1961, Copyright © 1994 by American Physiological Society

ARTICLES

Ontogeny of NO activity and response to inhaled NO in the developing ovine pulmonary circulation

J. P. Kinsella, D. D. Ivy and S. H. Abman
Department of Pediatrics, Children's Hospital, Denver, Colorado.

To determine maturation-related changes in nitric oxide (NO) activity in the developing pulmonary circulation, we studied the hemodynamic effects of endogenous NO inhibition under basal conditions in the premature ovine fetus and the response to birth-related stimuli and exogenous NO in 30 fetal sheep at three different gestational ages. At 0.95 term, pulmonary vasodilation during inhaled NO (20 parts per million) was equivalent to the dilator response to 100% O2, but at 0.86 term vasodilation during inhaled NO was greater than the dilator response to 100% O2 (P < 0.05). At 0.78 term, left pulmonary arterial flow (QLPA) did not increase with exposure to either NO or 100% O2. Intrapulmonary infusion of nitro-L-arginine (L-NA) increased basal pulmonary vascular resistance 38% in the premature fetus at 0.78 term. L-NA treatment decreased the ventilation-induced rise in QLPA by 60% compared with controls (P < 0.05). Inhaled NO but not 100% O2 increased QLPA after L-NA treatment to levels achieved with ventilation alone in the controls. We conclude that in the premature pulmonary circulation (0.78 term) 1) basal pulmonary vascular resistance is modulated by endogenous NO, 2) pulmonary vasodilation at birth is partly mediated by endogenous NO activity, and 3) inhaled NO causes potent vasodilation.

This article has been cited by other articles:

				P. Deruelle, T. R. Grover, and S. H. Abman Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L798 - L806. [Abstract] [Full Text] [PDF]

				P. Deruelle, T. R. Grover, L. Storme, and S. H. Abman Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L727 - L733. [Abstract] [Full Text] [PDF]

				M Shochina, Y Fellig, M Sughayer, G Pizov, K Vitner, D Podeh, A Hochberg, and I Ariel Nitric oxide synthase immunoreactivity in human bladder carcinoma Mol. Pathol., August 1, 2001; 54(4): 248 - 252. [Abstract] [Full Text] [PDF]

				V. Hampl and J. Herget Role of Nitric Oxide in the Pathogenesis of Chronic Pulmonary Hypertension Physiol Rev, October 1, 2000; 80(4): 1337 - 1372. [Abstract] [Full Text] [PDF]

				K. Nakanishi, F. Tajima, H. Itoh, Y. Nakata, N. Hama, O. Nakagawa, K. Nakao, T. Kawai, C. Torikata, T. Suga, et al. Expression of C-type natriuretic peptide during development of rat lung Am J Physiol Lung Cell Mol Physiol, November 1, 1999; 277(5): L996 - L1002. [Abstract] [Full Text] [PDF]

				J. P. Kinsella Clinical Trials of Inhaled Nitric Oxide Therapy in the Newborn Pediatr. Rev., November 1, 1999; 20(11): e110 - e113. [Full Text] [PDF]